You are here

Article Text

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Oral Presentations. Abstract session: Vasculitis
OP0234 Effects of Anticoagulant Treatment on the Incidence of New Vascular Events in Patients with Behcet's Disease with Vascular Involvement
  1. F. Alibaz-Oner1,
  2. A. Karadeniz2,
  3. S. Yilmaz3,
  4. A. Balkarlı4,
  5. V. Cobankara4,
  6. A. Yazıcı5,
  7. A. Cefle5,
  8. G. Kimyon6,
  9. B. Kisacik6,
  10. A.M. Onat6,
  11. F. Yildiz7,
  12. E. Erken7,
  13. S.Y. Bilge8,
  14. T. Kasifoglu8,
  15. G. Yildirim Cetin9,
  16. M. Sayarlıoglu10,
  17. H. Direskeneli1
  1. 1Rheumatology
  2. 2Internal Medicine, Marmara University, School of Medicine, Istanbul
  3. 3Rheumatology, Selcuk University, School of Medicine, Konya
  4. 4Rheumatology, Pamukkale University, School of Medicine, Denizli
  5. 5Rheumatology, Kocaeli University, School of Medicine, Kocaeli
  6. 6Rheumatology, Gaziantep University, School of Medicine, Gaziantep
  7. 7Rheumatology, Cukurova University, School of Medicine, Adana
  8. 8Rheumatology, Eskisehir Osmangazi University, School of Medicine, Eskisehir
  9. 9Rheumatology, Kahramanmaras Sutcu Imam University, School of Medicine, Kahramanmaras
  10. 10Rheumatology, Samsun Ondokuz Mayıs University, School of Medicine, Samsun, Turkey

Abstract

Background Vascular involvement (VI) is one of the major causes of mortality and morbidity in Behcet's Disease (BD). There are no controlled studies for the management of major vascular involvement in BD. According to the EULAR recommendations for the management of BD, only immunosuppressive (IS) agents such as corticosteroids, azathioprine, cyclophosphamide or cyclosporine A are recommended for VI.

Objectives In this study, we aimed to investigate the effects of anticoagulant (AC) treatment on the development of new vascular events in patients with BD followed up for vascular disease, retrospectively.

Methods In this retrospective study, 637 patients with BD (F/M: 283/354, mean age: 38.5±11.1 years) classified according to ISG criteria from 8 Rheumatology centers in Turkey, were included. The demographic data, clinical characteristics of first vascular event and relapses, treatment protocols and data about complications were acquired from files, retrospectively.

Results Two hundred eighty-one BD patients (44.1%) were of mucocutaneus type, whereas 356 patients (55.9%) had major organ involvement [Uveitis: 42.4% (n=270), VI: 20.6% (n=131), neurologic involvement: 6.9% (n=44)]. VI developed in 131 patients during the follow-up. When the first vascular event developed, the mean disease duration was 3.5 (0-28) years and mean age was 33.2±8 years. After the first vascular event, IS treatment was given to 88.5% (n=105) and AC treatment to 62.6% (n=76) of the patients. Minor hemorrhage (as a complication related to AC treatment) was observed in 3 (3.9%) patients. A second vascular event developed in 47 (35.9%) patients. The rate of new vascular event development was similar between the patients taking only ISs and AC plus IS treatments after first vascular event (27.2% vs 29.6%, p=0.78). Relapse rate was significantly higher in group taking only ACs than taking only ISs (91.6%, p=0.002). During follow-up, a third vascular event developed in 11 patients. The rate of new vascular event development was again similar between the patients taking only IS and AC plus IS treatments. There was no relationship between the total duration of AC treatment and number of vascular events. However, total number of vascular events negatively correlated with the age during the first vascular event (r:-0.215, p=0.02). Treatment rates of before and after vascular events showed a severe compliance problem during the follow-up (Figure 1).

Figure 1.
Figure 1.

Immunosuppresive and anticoagulant treatments rates before and after vascular events.

Conclusions In this study, we did not find any extra effect of AC treatment adding on to IS treatment in the course of vascular involvement in patients with BD. Severe complications related to AC treatment were also not detected. Our results suggest that there is a severe compliance problem in BD patients with VI during follow-up.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3394

https://doi.org/10.1136/annrheumdis-2014-eular.3394

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.